Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD of Prelude Therapeutics Inc from Q3 2020 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Prelude Therapeutics Inc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from Q3 2020 to Q3 2025.
- Prelude Therapeutics Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2025 was -$19.7M, a 38% increase year-over-year.
- Prelude Therapeutics Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Sep 2025 was -$112M, a 14.4% increase year-over-year.
- Prelude Therapeutics Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$127M, a 6.21% decline from 2023.
- Prelude Therapeutics Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$120M, a 3.01% decline from 2022.
- Prelude Therapeutics Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$116M, a 3.57% decline from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)